Focused On-demand Library for Signal-induced proliferation-associated 1-like protein 3

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

O60292

UPID:

SI1L3_HUMAN

Alternative names:

SPA-1-like protein 3

Alternative UPACC:

O60292; Q2TV87

Background:

Signal-induced proliferation-associated 1-like protein 3, also known as SPA-1-like protein 3, plays a pivotal role in lens epithelial cell morphogenesis, polarity, adhesion, and cytoskeletal organization. This protein's involvement is crucial for maintaining the clarity and proper function of the lens, as highlighted in research findings (PubMed:26231217).

Therapeutic significance:

Cataract 45, a condition characterized by the opacification of the lens leading to visual impairment or blindness, is directly associated with variants affecting this protein. Understanding the role of Signal-induced proliferation-associated 1-like protein 3 could open doors to potential therapeutic strategies for this and possibly other related ocular diseases.